Mascola, John R., Lewis, Mark G., Stiegler, Gabriela, Harris, Dawn, VanCott, Thomas C., Hayes, Deborah, ...
The role of antibody in protection against human immunodeficiency virus (HIV-1) has been difficult to study in animal models because most primary HIV-1 strains do not infect nonhuman primates. Using...
Zwick, Michael B., Labrijn, Aran F., Wang, Meng, Spenlehauer, Catherine, Saphire, Erica Ollmann, Binley, James M., ...
The identification and epitope mapping of broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies (Abs) is important for vaccine design, but, despite much effort, very few...
Hofmann-Lehmann, Regina, Vlasak, Josef, Rasmussen, Robert A., Smith, Beverly A., Baba, Timothy W., Liska, Vladimir, ...
To develop prophylaxis against mother-to-child human immunodeficiency virus (HIV) transmission, we established a simian-human immunodeficiency virus (SHIV) infection model in neonatal macaques that...
Membrane-Anchored Peptide Inhibits Human Immunodeficiency Virus Entry
Hildinger, Markus, Dittmar, Matthias T., Schult-Dietrich, Patricia, Fehse, Boris, Schnierle, Barbara S., Thaler, Sonja, ...
Peptides derived from the heptad repeats of human immunodeficiency virus (HIV) gp41 envelope glycoprotein, such as T20, can efficiently inhibit HIV type 1 (HIV-1) entry. In this study, replication of...
Zwick, Michael B., Wang, Meng, Poignard, Pascal, Stiegler, Gabriela, Katinger, Hermann, Burton, Dennis R., ...
Several reports have described the existence of synergy between neutralizing monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 (HIV-1). Synergy between human MAbs b12, 2G12,...
Wolbank, Susanne, Kunert, Renate, Stiegler, Gabriela, Katinger, Hermann
We have previously generated human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1) antibodies 2F5IgG and 2G12IgG with an exceptional cross-clade neutralizing potential. 2F5IgG and...
Mascola, John R., Lewis, Mark G., VanCott, Thomas C., Stiegler, Gabriela, Katinger, Hermann, Seaman, Michael, ...
High levels of infused anti-human immunodeficiency virus type 1 (HIV-1) neutralizing monoclonal antibodies (MAbs) can completely protect macaque monkeys against mucosal chimeric simian-human...
Zhang, Lei, Ribeiro, Ruy M., Mascola, John R., Lewis, Mark G., Stiegler, Gabriela, Katinger, Hermann, ...
Passive antibody treatment of macaques prior to simian/human immunodeficiency virus infection produces “sterilizing immunity” in some animals and long-term reductions in viral loads in others....
Binley, James M., Wrin, Terri, Korber, Bette, Zwick, Michael B., Wang, Meng, Chappey, Colombe, ...
Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been intensively studied, but we...
Mehandru, Saurabh, Wrin, Terri, Galovich, Justin, Stiegler, Gabriela, Vcelar, Brigitta, Hurley, Arlene, ...
As the AIDS epidemic continues unabated, the development of a human immunodeficiency virus (HIV) vaccine is critical. Ideally, an effective vaccine should elicit cell-mediated and neutralizing...
Zwick, Michael B., Jensen, Richard, Church, Sarah, Wang, Meng, Stiegler, Gabriela, Kunert, Renate, ...
The conserved membrane-proximal external region (MPER) of human immunodeficiency virus type 1 (HIV-1) gp41 is a target of two broadly neutralizing human monoclonal antibodies, 2F5 and 4E10, and is an...
Rusert, Peter, Kuster, Herbert, Joos, Beda, Misselwitz, Benjamin, Gujer, Cornelia, Leemann, Christine, ...
We studied the effect of entry inhibitors on 58 virus isolates derived during acute and chronic infection to validate these inhibitors in vitro and to probe whether viruses at early and chronic...
Kittel, Christian, Ferko, Boris, Kurz, Martina, Voglauer, Regina, Sereinig, Sabine, Romanova, Julia, ...
Engineering of the influenza A virus NS1 protein became an attractive approach to the development of influenza vaccine vectors since it can tolerate large inserts of foreign proteins. However,...
Joos, Beda, Trkola, Alexandra, Kuster, Herbert, Aceto, Leonardo, Fischer, Marek, Stiegler, Gabriela, ...
While certain antibodies directed against the human immunodeficiency virus (HIV) envelope have the potential to suppress virus replication in vitro, the impact of neutralizing antibodies in vivo...
Mascola, John R., Lewis, Mark G., Stiegler, Gabriela, Harris, Dawn, VanCott, Thomas C., Hayes, Deborah, ...
The role of antibody in protection against human immunodeficiency virus (HIV-1) has been difficult to study in animal models because most primary HIV-1 strains do not infect nonhuman primates. Using...
Zwick, Michael B., Labrijn, Aran F., Wang, Meng, Spenlehauer, Catherine, Saphire, Erica Ollmann, Binley, James M., ...
The identification and epitope mapping of broadly neutralizing anti-human immunodeficiency virus type 1 (HIV-1) antibodies (Abs) is important for vaccine design, but, despite much effort, very few...
Hofmann-Lehmann, Regina, Vlasak, Josef, Rasmussen, Robert A., Smith, Beverly A., Baba, Timothy W., Liska, Vladimir, ...
To develop prophylaxis against mother-to-child human immunodeficiency virus (HIV) transmission, we established a simian-human immunodeficiency virus (SHIV) infection model in neonatal macaques that...
Membrane-Anchored Peptide Inhibits Human Immunodeficiency Virus Entry
Hildinger, Markus, Dittmar, Matthias T., Schult-Dietrich, Patricia, Fehse, Boris, Schnierle, Barbara S., Thaler, Sonja, ...
Peptides derived from the heptad repeats of human immunodeficiency virus (HIV) gp41 envelope glycoprotein, such as T20, can efficiently inhibit HIV type 1 (HIV-1) entry. In this study, replication of...
Zwick, Michael B., Wang, Meng, Poignard, Pascal, Stiegler, Gabriela, Katinger, Hermann, Burton, Dennis R., ...
Several reports have described the existence of synergy between neutralizing monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 (HIV-1). Synergy between human MAbs b12, 2G12,...
Wolbank, Susanne, Kunert, Renate, Stiegler, Gabriela, Katinger, Hermann
We have previously generated human monoclonal anti-human immunodeficiency virus type 1 (anti-HIV-1) antibodies 2F5IgG and 2G12IgG with an exceptional cross-clade neutralizing potential. 2F5IgG and...
Mascola, John R., Lewis, Mark G., VanCott, Thomas C., Stiegler, Gabriela, Katinger, Hermann, Seaman, Michael, ...
High levels of infused anti-human immunodeficiency virus type 1 (HIV-1) neutralizing monoclonal antibodies (MAbs) can completely protect macaque monkeys against mucosal chimeric simian-human...
Zhang, Lei, Ribeiro, Ruy M., Mascola, John R., Lewis, Mark G., Stiegler, Gabriela, Katinger, Hermann, ...
Passive antibody treatment of macaques prior to simian/human immunodeficiency virus infection produces “sterilizing immunity” in some animals and long-term reductions in viral loads in others....
Binley, James M., Wrin, Terri, Korber, Bette, Zwick, Michael B., Wang, Meng, Chappey, Colombe, ...
Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been intensively studied, but we...
Mehandru, Saurabh, Wrin, Terri, Galovich, Justin, Stiegler, Gabriela, Vcelar, Brigitta, Hurley, Arlene, ...
As the AIDS epidemic continues unabated, the development of a human immunodeficiency virus (HIV) vaccine is critical. Ideally, an effective vaccine should elicit cell-mediated and neutralizing...
Zwick, Michael B., Jensen, Richard, Church, Sarah, Wang, Meng, Stiegler, Gabriela, Kunert, Renate, ...
The conserved membrane-proximal external region (MPER) of human immunodeficiency virus type 1 (HIV-1) gp41 is a target of two broadly neutralizing human monoclonal antibodies, 2F5 and 4E10, and is an...
Rusert, Peter, Kuster, Herbert, Joos, Beda, Misselwitz, Benjamin, Gujer, Cornelia, Leemann, Christine, ...
We studied the effect of entry inhibitors on 58 virus isolates derived during acute and chronic infection to validate these inhibitors in vitro and to probe whether viruses at early and chronic...
Kittel, Christian, Ferko, Boris, Kurz, Martina, Voglauer, Regina, Sereinig, Sabine, Romanova, Julia, ...
Engineering of the influenza A virus NS1 protein became an attractive approach to the development of influenza vaccine vectors since it can tolerate large inserts of foreign proteins. However,...
Joos, Beda, Trkola, Alexandra, Kuster, Herbert, Aceto, Leonardo, Fischer, Marek, Stiegler, Gabriela, ...
While certain antibodies directed against the human immunodeficiency virus (HIV) envelope have the potential to suppress virus replication in vitro, the impact of neutralizing antibodies in vivo...
In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10▿
Manrique, Amapola, Rusert, Peter, Joos, Beda, Fischer, Marek, Kuster, Herbert, Leemann, Christine, ...
Recently, passive immunization of human immunodeficiency virus (HIV)-infected individuals with monoclonal antibodies (MAbs) 2G12, 2F5, and 4E10 provided evidence of the in vivo activity of 2G12 but...
Mehandru, Saurabh, Vcelar, Brigitta, Wrin, Terri, Stiegler, Gabriela, Joos, Beda, Mohri, Hiroshi, ...
Three neutralizing monoclonal antibodies (MAbs), 2G12, 2F5, and 4E10, with activity in vitro and in vivo were administered in an open-label, nonrandomized, proof-of-concept study to attempt to...
Trkola, Alexandra, Kuster, Herbert, Rusert, Peter, Von Wyl, Viktor, Leemann, Christine, Weber, Rainer, ...
The definition of plasma neutralizing antibody titers capable of controlling human immunodeficiency virus (HIV) infection in vivo is considered a critical step in vaccine development. Here we provide...
Huber, Michael, Von Wyl, Viktor, Ammann, Christoph G., Kuster, Herbert, Stiegler, Gabriela, Katinger, Hermann, ...
To evaluate the contribution of complement-mediated lysis to the in vivo activities of neutralizing antibodies, we analyzed the influence of complement activation on treatment success in a recent...
Cost-effective production of a vaginal protein microbicide to prevent HIV transmission
Ramessar, Koreen, Rademacher, Thomas, Sack, Markus, Stadlmann, Johannes, Platis, Dimitris, Stiegler, Gabriela, ...
A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based...